Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Triple Negative Breast Neoplasms × Vinorelbine × Clear all

Phase

Status

Unknown 3 Completed 3 Active not recruiting 3 Terminated 1 Recruiting 1 Not yet recruiting 1 No longer available 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 7 Neoplasms 2 Neoplasm Metastasis 2 Hodgkin Disease 2 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Mesothelioma 1 Malignant Solid Tumour 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma 1 Breast Neoplasms, Male 1 Advanced Non-Small Cell Lung Cancer 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 17 Carboplatin 11 Cyclophosphamide 10 atezolizumab 9 Paclitaxel 7 Capecitabine 6 fludarabine 5 Nivolumab 5 Albumin-Bound Paclitaxel 5 talazoparib 4 Taxes 4 Gemcitabine 4 Cisplatin 4 130-nm albumin-bound paclitaxel 4 spartalizumab 3 entinostat 3 bintrafusp alfa protein, human 3 avelumab 3 Docetaxel 3 Biopsy 3 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3 trilaciclib 2 sacituzumab govitecan 2 durvalumab 2 bicalutamide 2 aldesleukin 2 Trastuzumab 2 Magnetic Resonance Imaging 2 Leucovorin 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03358004 2018-10-05

VICTOR3

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡